Novartis is continuing its multiyear overhaul with new plans to shutter its production facility in Wehr, Germany, by 2028. The move, announced Tuesday, will eliminate about 220 jobs, according to Novartis.
The German vaccine maker plans to wind down operations at a handful of its sites in Germany plus one in Singapore, putting as many as 1,860 jobs on the chopping block.
Fresh off gaining an FDA expansion for Auvelity as a treatment for agitation associated with Alzheimer’s disease, Axsome Therapeutics has projected peak sales for the non-antipsychotic drug to reach $8 billion.
Sanofi is supercharging its artificial intelligence capabilities. The French pharma is investing $294 million to expand its global AI center of excellence in Toronto, kicking off a scale-up of the digital infrastructure it built at the Canadian hub four years ago.
A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD patients.
A new study suggests travel could be a surprisingly powerful anti-aging tool. By viewing tourism through the lens of entropy, researchers found that positive travel experiences may help the body stay balanced and resilient. Activities like exploring new places, staying active, and connecting with others can boost immunity, metabolism, and stress recovery. However, stressful or unsafe travel could
France's medicines regulator has fined Novo Nordisk and Eli Lilly over their weight loss ad campaigns.
The 5th Circuit’s ruling on mifepristone “is bad for health care access, and it’s also bad for innovation,” writes Grace E. Colón.
Though largely operating in the background until recently, Prolific Machines’ optogenetic approach to biomanufacturing is set to make waves thanks to the achievement of an impressive milestone in monoclonal antibody manufacturing.
The Supreme Court on Monday restored broad access to the abortion pill mifepristone, blocking a ruling that had threatened to upend one of the main ways abortion is provided across the…
A research letter published on Monday in JAMA Pediatrics argues that paternal mortality deserve more attention
It's tough to write nuanced headlines, but a new study on AI in emergency rooms is getting way overhyped.
The U.S. Supreme Court has temporarily reinstated online access to the abortion pill mifepristone after a federal appeals court in New Orleans ruled to prevent mifepristone from being prescribed over the phone and sent through the mail in the U.S. while a Louisiana lawsuit plays out.
A new study suggests a surprisingly simple compound could help fight Alzheimer’s disease. Researchers found that arginine—an inexpensive amino acid already considered safe—can reduce the buildup of toxic amyloid proteins in the brain, a hallmark of the disease. In animal models, oral arginine not only lowered harmful protein deposits but also improved behavior and reduced brain inflammation.
The company chalks up a financial impact of about 150 billion Korean won ($102 million) from "preemptive production adjustments" made to mitigate potential manufacturing impacts, a spokesperson said.
After submitting plans to cut 114 jobs tied to its U.S. headquarters in New Jersey in March, Novartis late last month added a handful of additional roles from the East Hanover site to its multiyear workforce reduction agenda.
Bristol Myers Squibb is warming up for the FIFA World Cup 2026 with a new media campaign, launching its “Won’t Lose” ad ahead of the soccer community arriving in the U.S. for this summer’s tournament.
Creatine might be famous in the gym, but its real story is far more interesting. Naturally produced in the body, it helps power cells by rapidly regenerating ATP—the fuel that keeps muscles, the brain, and even the heart running during intense activity. Supplementing with creatine can boost short bursts of physical performance and may even support memory, mood, and cognitive speed, especially in p
A new study suggests depression may soon be detectable through a simple blood test—by tracking how certain immune cells age. Researchers found that accelerated aging in monocytes, a type of white blood cell, is closely tied to the emotional and cognitive symptoms of depression, like hopelessness and loss of pleasure, rather than physical symptoms such as fatigue.
GLP-1 drugs like semaglutide—best known for treating diabetes and driving weight loss under the brand names Ozempic and Wegovy—may also deliver a surprising mental health boost. In a massive study tracking nearly 100,000 people over more than a decade, researchers found that these medications were linked to significantly fewer psychiatric hospital visits and sick days.